UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

Patients eligible to be treated on this status are status post allogeneic hematopoietic stem cell transplantation for a neoplastic hematologic disorder with the need of a CD34 selected stem cell boost for graft failure or low graft function (e.g. marrow cellularity reduced per age and/or dropping donor chimerism with cytopenias and/or platelets or red blood cells transfusion requirement).

Inclusion criteria

• AML in morphologic remission with intermediate/high-risk features or relapsed disease 1 or 2
• ALL in morphologic remission with high-risk features or relapsed disease 1 or 2
• Lymphoid malignancies in CR or PR (e.g. non-Hodgkin's lymphoma, prolymphocytic leukemia, CLL)
• Myelodysplastic syndromes with <=10% blasts
• CML in morphologic remission after blast phase or accelerated phase
• Primary myelofibrosis with <=10% blasts ^morphologic remission is defined as <5% blasts on the bone marrow biopsy. Negative test for donor-specific antibody within 28 days of starting conditioning regimen, or adequate for standard desensitization protocol.

Exclusion criteria

• Non-compliant patients.
• No appropriate caregivers identified.
• Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
• Patients with known allergy to DMSO.
• Pregnant or breastfeeding women